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Background: Pulmonary rehabilitation improves outcomes in patients with interstitial lung dis-
ease (ILD), however it is unclear whether these effects are long lasting and which patients
benefit most.
Methods: Patients with ILD were recruited into this prospective cohort study from three pul-
monary rehabilitation programs. Patients completed functional assessments (6-minute walk
distance (6MWD), and 4-meter walk time) and surveys (quality of life, dyspnea, depression,
and physical activity) before rehabilitation, after rehabilitation, and at six months. Changes
from baseline were compared using a paired t-test. Independent predictors of change in
6MWD and quality of life were determined using multivariate analysis.
Results: Fifty-four patients were recruited (22 with idiopathic pulmonary fibrosis), 50 patients
(93%) completed the rehabilitation program, and 39 returned for six-month follow-up. 6MWD
improved 57.6 m immediately after rehabilitation (95% confidence interval (CI) 40.2
e75.1 m, p < 0.0005), and remained 49.8 m above baseline at six months (95%CI 15.0
e84.6 m, p Z 0.005). The majority of patients achieved the minimum clinically importantspital, 1081 Burrard St, Ward 8B, Vancouver, BC V6Z 1Y6, Canada. Tel.: þ1 604 806 8818; fax: þ1 604
i.ubc.ca, cjryerson@gmail.com (C.J. Ryerson).
3 Elsevier Ltd. All rights reserved.
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204 C.J. Ryerson et al.difference for quality of life (51%), dyspnea (65%), and depression score (52%) immediately af-
ter rehabilitation, and improvements were still significant at 6-month follow-up for quality of
life, depression, and physical activity. A low baseline 6MWD was the only independent predic-
tor of improvement in 6MWD during rehabilitation (r Z 0.49, p < 0.0005). Change in 6MWD
was an independent predictor of change in quality of life (r Z 0.36, p Z 0.01).
Conclusions: Pulmonary rehabilitation improved multiple short- and long-term outcomes in pa-
tients with ILD. While all patients appear to benefit, ILD patients with a low baseline 6MWD had
greater benefit from rehabilitation.
Clinical trials registration number: NCT01055730 (clinicaltrials.gov).
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Pulmonary rehabilitation is a structured exercise and edu-
cation program that was developed for patients with
chronic lung diseases such as chronic obstructive pulmonary
disease (COPD) [1]. Pulmonary rehabilitation is an estab-
lished treatment for COPD that improves functional ca-
pacity (i.e. 6-minute walk distance; 6MWD) and symptoms
of dyspnea [2]. More recent research has investigated the
role of pulmonary rehabilitation in other chronic lung dis-
eases e in particular interstitial lung disease (ILD) [3e8].
ILD is a group of conditions that cause scarring or
inflammation in the lungs, often resulting in significant
morbidity and high mortality. Almost all ILDs are charac-
terized by dyspnea and functional limitation, and there are
few effective and/or well-tolerated pharmacotherapies for
many ILD subtypes. Two small randomized trials and several
cohort studies suggest that pulmonary rehabilitation im-
proves functional capacity, quality of life, and dyspnea in
ILD [3e8]. However it is unknown whether pulmonary
rehabilitation improves other outcomes such as depression,
physical activity, and muscle strength, whether these
benefits are sustained following rehabilitation, and which
patients experience the greatest benefits. Based on these
results, recent clinical practice guidelines recommend
pulmonary rehabilitation be considered in the management
of ILD patients, but note that the quality of the data sup-
porting its use is low and that the long-term benefit remains
unclear [9].
We conducted a prospective cohort study of patients
with ILD undergoing pulmonary rehabilitation with three
main objectives: 1) To determine the short-term and long-
term impact of pulmonary rehabilitation on functional and
symptomatic outcomes; 2) to define the baseline factors
that predict functional change post-rehabilitation; and 3)
to characterize the relationship of changes in quality of life
to changes in function and symptom scores.Materials and methods
Study patients
Patients were prospectively recruited between 2010 and
2012 from three pulmonary rehabilitation programs: John
Muir Health (Concord, CA, USA), St. Paul’s Hospital (Van-
couver, BC, Canada), and Seton Medical Center (Daly City,CA, USA). Patients required a diagnosis of ILD from their
treating physician and referral to a participating pulmonary
rehabilitation program. ILD diagnosis was recorded using
standard criteria where available [9e14]. All patients were
required to speak and read English, and be able to return
for a six-month follow-up visit. All ILD subtypes were
eligible for inclusion. The Institutional Review Boards
approved the protocol at each institution (see Online data
supplement for details). All study patients provided writ-
ten informed consent.
Pulmonary rehabilitation program
All patients were enrolled in a pulmonary rehabilitation
program that conformed to standard ATS/ERS recommen-
dations [1]. Programs lasted between six and nine weeks
and included twice-weekly sessions of monitored, super-
vised exercise. The recommended exercise regimen was
individually tailored to each patient according to his or her
level of functional impairment, severity of ILD (e.g. hyp-
oxemia), presence of comorbid disease, and any other po-
tential factors that could limit intensity or safety of
exercise. An exercise prescription was developed for each
patient based on medical history, clinical findings and six-
minute walk test. The prescription included upper and
low extremity training with a designated mode (walking,
bicycle and or sitting elliptical trainer), frequency (3e5
times a week), duration of exercise (usually > 20 min but
may begin with very short intervals based on clinical find-
ings), and exercise intensity (Borg dyspnea score of 3e6
points) [1]. Patients also attended educational sessions on
topics including symptom control, use of oxygen, and dis-
ease self-management strategies.
Measurements
Patients were assessed on the first and last scheduled days
of pulmonary rehabilitation, and six months following their
first pulmonary rehabilitation session. Baseline variables
collected at the first visit included age, gender, history of
smoking, ILD subtype, the use of medications for treatment
of ILD, and the presence of comorbid disease that could
impact exercise ability. Patients were specifically asked if
they were using azathioprine, bosentan, cyclophospha-
mide, methotrexate, mycophenolate, acetylcysteine, or
prednisone, or if they had a history of cardiac, peripheral
vascular, lung airway, pulmonary vascular, neuromuscular,
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formed according to standard techniques [15,16].
A functional assessment was performed and symptom-
based questionnaires were administered at each study visit.
The 6-minute walk distance (6MWD) was performed ac-
cording to recommended criteria [17], and the percent-
predicted 6MWD was calculated based on gender, age,
height, and weight as previously reported [18]. The 6MWD
has a reported minimum clinically important difference
(MCID) of 28 m in patients with IPF [19], and was pre-
specified as the primary endpoint. Muscle function was
measured using the 4-meter walk time and 4-meter walk
speed, which are validated geriatric measures of functional
status that are based on the time it takes a patient to walk
4 m at their normal pace [20]. These values are primarily
influenced by lower extremity muscle strength [21], and
have previously been used in patients with ILD [22].
Community-dwelling older adults typically have walk
speeds above 0.90 m/s [23]. Patients were allowed the use
of oxygen or gait aids (e.g. cane, walker) during these tests.
General level of physical activity was measured using the
self-reported Rapid Assessment of Physical Activity ques-
tionnaire (RAPA), a 7-point questionnaire that identifies the
extent of physical activity conducted on a weekly basis
[24].
Symptomatic endpoints included unmodified question-
naires for quality of life, dyspnea, and depression. Quality
of life was determined using the St. George’s Respiratory
Questionnaire (SGRQ) [25,26], a 50-item questionnaire
commonly used in ILD clinical research. The performance of
the SGRQ has been evaluated in patients with IPF, with an
MCID of 5e8 points [27]. Dyspnea was measured using the
University of California San Diego Shortness of Breath
Questionnaire (UCSD SOBQ) [28]. The UCSD SOBQ is a 24-
item questionnaire that has longitudinal construct validity
in IPF [29], with a reported MCID of 5 points in patients with
chronic respiratory disease [30,31]. Depression was
measured by the 15-item Geriatric Depression Scale (GDS)
that has an MCID of 1 point [32]. Patients also reported a
global assessment of overall change in both their exercise
capacity (ability to walk) and quality of life since the
beginning of their pulmonary rehabilitation program. This
was based on a standardized question with a 15-level
response that ranged from “A very great deal worse” to
“A very great deal better.”Statistical analysis
Data are described using mean (standard deviation) unless
otherwise indicated. Baseline characteristics of patients
lost to follow-up were compared to those who completed
the study using a Chi-square, t-test, or Wilcoxon rank sum
test. Comparison of baseline and follow-up measurements
was made with repeated measures linear regression, using
an unstructured correlation matrix and the “robust” option
that provides valid confidence intervals even when speci-
fying an incorrect correlation structure. Repeated-
measures analysis is less prone to bias from non-random
losses to follow-up compared to complete-case analysis or
imputation, and has been used previously in similar ana-
lyses [7]. We performed separate analyses for evaluation ofshort-term and long-term impact of pulmonary rehabilita-
tion. Short-term impact was analyzed by comparing values
obtained at visit 1 (pre-rehabilitation) and visit 2 (post-
rehabilitation), and long-term impact by comparing visit 1
(pre-rehabilitation) and visit 3 (follow-up).
Baseline predictors of change in 6MWD were first eval-
uated on bivariate analysis using a t-test or Spearman rank
correlation coefficient. Predictors with a bivariate p < 0.20
were evaluated in a stepwise multivariate model using
backward selection to identify independent predictors of
change in 6MWD. A p value threshold of 0.20 was used to
rule out confounding with greater certainty. A p value
<0.05 was required for retention in the final multivariate
model. Absolute changes in outcomes over time were
calculated by subtracting the visit 1 (pre-rehabilitation)
value from the visit 2 (post-rehabilitation). Potential asso-
ciation of change variables with change in SGRQ was tested
using bivariate and multivariate analyses as described
above. All data analysis was performed using STATA 11.2
(StataCorp, Texas, USA).Results
Study patients
A total of 54 patients were recruited from the three
participating centers (Table 1). The most common diagnosis
was IPF (n Z 22, 41%). Most patients were on medication
for their ILD (n Z 31, 57%), with prednisone used most
commonly (n Z 22, 41%). Patients on average had moder-
ate functional and physiological impairment reflected by
the baseline 6MWD, FVC, and DLCO. Ten patients (19%) had
a 4-meter walk speed <0.90 m/s (the lower estimate of
walk speed for community-dwelling older adults) [23].
Fifty patients (93%) completed the pulmonary rehabili-
tation program and 39 patients (72%) returned for the six-
month follow-up visit (Fig. 1). Patients attended an average
of 15 rehabilitation sessions (range 10e24) over an average
of 7 weeks (range 6e9). Four patients died during the
study; 2 deaths during the pulmonary rehabilitation period
and 2 deaths during the follow-up period. Baseline char-
acteristics of the 15 patients lost to six-month follow-up
were similar to those that completed the study
(Supplemental Table 1).Short-term impact of pulmonary rehabilitation
There was short-term improvement following rehabilitation
in all functional measures (6MWD, 4-meter walk time,
physical activity) and symptom questionnaires (quality of
life, dyspnea, depression) (Figs. 2 and 3). 6MWD improved
57.6 m (95% confidence interval (CI) 40.2 to 75.1,
p < 0.0005), and 34 patients (68%) improved by more than
28 m (the MCID in ILD) [19]. Quality of life score (SGRQ)
improved 6.1 points (95%CI 3.7 to 8.6, p < 0.0005), with 51%
of patients achieving a 5-point or greater improvement, and
38% improving by at least 8 points. The majority of patients
achieved the MCID for dyspnea (65%) and depression (52%),
and 81% also reported global improvement in their exercise
capacity and quality of life (Supplemental Figs. 1(A) and
Table 1 Baseline characteristics.
Variable Mean (SD) or Number
(%) (n Z 54)




Unclassifiable ILD 8 (15%)
















Other immune suppressant 7 (13%)
No ILD treatment 23 (43%)
6MWD, m 366 (120)
6MWD, % predicted 77 (23)




FVC, % predicted 69.2 (21.2)
DLCO, % predicted 46.8 (12.6)
Abbreviations: 6MWD, 6-minute walk distance; DLCO, diffusing
capacity of carbon monoxide; FVC, forced vital capacity; ILD,
interstitial lung disease; IPF, idiopathic pulmonary fibrosis; NAC,
N-acetylcysteine; NSIP, nonspecific interstitial pneumonia; SD,
standard deviation.
a Other ILD diagnoses included scleroderma (n Z 3), sarcoid
(3), aspiration-induced ILD (2), hypersensitivity pneumonitis
(2), undifferentiated connective-tissue disease-related ILD (2),
asbestosis (1), chronic eosinophilic pneumonia (1), dermato-
myositis (1), familial pulmonary fibrosis (1), lymphangioleio-
myomatosis (1), organizing pneumonia (1), and radiation
pneumonitis (1).
b Other treatments included azathioprine (n Z 4), mycophe-
nolate (2), cyclophosphamide (1), and methotrexate (1).
Figure 1 Study population.
206 C.J. Ryerson et al.2(A)). Effects were similar in the IPF and non-IPF subgroups
and across all sites.
Long-term impact of pulmonary rehabilitation
There was long-term improvement in 6MWD, physical ac-
tivity, quality of life, and depression (Figs. 2 and 3).
Average 6MWD remained improved over baseline by
49.8 m (95%CI 15.0e84.7 m, p Z 0.005) at 6-month follow-
up. There was no impact of ILD subtype (IPF vs non-IPF ILD)
on the long-term change in 6MWD (p Z 0.44). Twenty-one
patients (55%) maintained an improvement of at least
28 m. The 4-meter walk time decreased non-significantly by0.24 s (95%CI 0.01e0.49 s, p Z 0.06). Self-reported
physical activity level improved by 0.83 points, as
assessed by the RAPA questionnaire (95%CI 0.28 to 1.38,
p Z 0.003). There remained statistically significant im-
provements over baseline in quality of life (3.6 points, 95%
CI 0.2 to 7.0, p Z 0.04) and depression (1.02 points, 95%CI
0 to 2.1, p Z 0.05) at 6-month follow-up, however the
improvement in dyspnea (4.0 points, 95%CI 1.5 to 9.5,
p Z 0.15) was not statistically significant. There was min-
imal change in self-reported global assessment of overall
change in functional capacity or quality of life compared to
pre-rehabilitation (Supplemental Figs. 1(B) and 2(B)).
Predictors of improvement following pulmonary
rehabilitation
Baseline 6MWD was the only predictor of change in 6MWD
on both bivariate and multivariate analysis (Table 2, Fig. 4).
Results were unchanged when using the percent-predicted
6MWD instead of the absolute value. For every 10-meter
greater 6MWD pre-rehabilitation, the change in 6MWD
post-rehabilitation declined by 2.63 m (95%CI 1.31 to 3.95,
p < 0.0005), however there was no specific threshold of
baseline 6MWD at which rehabilitation could be considered
ineffective. Baseline 4-meter walk time and level of phys-
ical activity were the only predictors of their subsequent
change (Supplemental Fig. 3). The use of prednisone and
recent initiation of treatment did not predict change in any
outcome variable.
Improvement in quality of life (SGRQ) was associated
with an improvement in 6MWD and depression score (GDS)
on bivariate analysis (Table 3). Change in 6MWD was the
only variable that predicted change in quality of life on
multivariate analysis (R2 Z 0.14; Table 3, Supplemental
Fig. 4). This association was independent of the initiation
of new treatments during the rehabilitation program and
was not influenced by ILD subtype.
Discussion
Our data suggest that pulmonary rehabilitation improves
functional capacity and quality of life in patients with a
variety ILDs, and that these benefits last for at least 6
Figure 2 Impact of pulmonary rehabilitation on functional endpoints. Box plots for (A) 6MWD, and (B) 4-meter walk time, and
histogram for (C) physical activity level, comparing values pre-pulmonary rehabilitation with post-pulmonary rehabilitation and at
6-month follow-up. *6-month follow-up data refer to measurements recorded six months after initiation of pulmonary rehabili-
tation. Abbreviations: 6MWD, 6-minute walk distance; RAPA, Rapid assessment of physical activity.
Pulmonary rehabilitation in interstitial lung disease 207months in most patients. The consistency and magnitude of
benefit across endpoints is substantial and markedly better
than pharmacological interventions that have been studied
in these diseases [33]. These data, combined with previous
studies [3e8], suggest that pulmonary rehabilitation should
be a first line therapy for patients with ILD.
Previous studies conflict on whether pulmonary reha-
bilitation is more beneficial in ILD patients with more se-
vere functional impairment [34,35]. This discordance mayFigure 3 Impact of pulmonary rehabilitation on quality of life,
dyspnea, and (C) depression, comparing values pre-pulmonary reha
up. *6-month follow-up data refer to measurements recorded six
tions: SGRQ, St. George’s Respiratory Questionnaire; UCSD SOBQ,
tionnaire; GDS, Geriatric depression scale.be due to differences in inclusion criteria and patient
population (e.g. types of ILD, ILD severity, presence of
comorbid disease) or study design (cohort vs randomized
trial). In our study, patients with worse baseline functional
capacity had greater improvements following pulmonary
rehabilitation, and we found that patients with baseline
walk distances as low as 120 m experienced clinically sig-
nificant improvement. This suggests that motivated pa-
tients with relatively severe functional impairment shoulddyspnea, and depression. Box plots for (A) quality of life, (B)
bilitation to post-pulmonary rehabilitation and 6-month follow-
months after initiation of pulmonary rehabilitation. Abbrevia-
University of California San Diego Shortness of Breath Ques-
Table 2 Baseline bivariate and multivariate predictors of
change in 6MWD following pulmonary rehabilitation.
Bivariate predictors r p Value
Age, years 0.00 1.00
Male e 0.07
Diagnosis of IPF e 0.44
Comorbidity e 0.96
Recent ILD treatmenta e 0.71
Chronic oxygen use e 0.61
Number of PR sessions attended 0.24 0.10
6MWD, m 0.49 <0.0005
6MWD SpO2 nadir, % 0.19 0.20
Physical activity (RAPA) 0.24 0.10
4-meter walk time, seconds 0.16 0.28
FVC, % predicted 0.04 0.81
DLCO, % predicted 0.10 0.54
Echocardiogram RVSP, mmHg 0.17 0.45
Multivariate analysis Regression coefficient p Value
6MWD, mb 2.63 <0.0005
r values are reported based on Spearman correlation co-
efficients between change in 6MWD (follow-up 6MWD e baseline
6MWD) and candidate predictor variables.
Abbreviations: 6MWD, 6-minute walk distance; DLCO, diffusing
capacity of carbon monoxide; FVC, forced vital capacity; ILD,
interstitial lung disease; IPF, idiopathic pulmonary fibrosis; PR,
pulmonary rehabilitation; RAPA, Rapid Assessment of Physical
Activity questionnaire; RVSP, right ventricular systolic pressure.
a Patients were considered to have recently started ILD
treatment if they had started any of prednisone, azathioprine,
methotrexate, cyclophosphamide, or mycophenolate within the
previous 3 months.
b Regression coefficient is reported per 10 m of baseline 6MWD
(i.e. for each 10 m increase in baseline 6MWD, 6MWD post-
rehabilitation declined by 2.63 m).
Figure 4 Association between baseline 6MWD and change in
6MWD after rehabilitation. Association between baseline and
change in 6MWD, stratified by ILD subtype (IPF vs non-IPF ILD).
The dashed line corresponds to the reported minimum clini-
cally important difference of the 6MWD in IPF. The baseline
6MWD is indicated by an “” for those patients who did not
complete the rehabilitation program. Abbreviations: 6MWD, 6-
minute walk distance; ILD, interstitial lung disease; IPF, idio-
pathic pulmonary fibrosis.
Table 3 Bivariate and multivariate correlates of improved
quality of life following pulmonary rehabilitation.
Bivariate predictorsa r p Value
6MWD 0.36 0.01
Physical activity (RAPA) 0.16 0.28
4-meter walk time, seconds 0.26 0.08
Dyspnea (UCSD SOBQ) 0.20 0.18
Depression (GDS) 0.32 0.03
Multivariate analysis Regression coefficient p Value
Change in 6MWDb 0.51 0.01
r values are reported based on Spearman correlation co-
efficients between change in quality of life (follow-up SGRQ e
baseline SGRQ) and candidate predictor variables.
Abbreviations: 6MWD, 6-minute walk distance; GDS, Geriatric
Depression Score; RAPA, Rapid Assessment of Physical Activity;
SGRQ, St. George’s Respiratory Questionnaire; UCSD SOBQ,
University of California San Diego Shortness of Breath
Questionnaire.
a All predictors are change in that variable comparing visit 2
(post-rehabilitation) to visit 1 (pre-rehabilitation).
b Regression coefficient is reported per 10 m of change in
6MWD post-rehabilitation (i.e. for each 10 m increase in 6MWD,
the SGRQ declined by 0.49 points).
208 C.J. Ryerson et al.still be offered pulmonary rehabilitation if the clinical
assessment suggests the potential for improvement in
functional and/or symptomatic outcomes. Conversely, pa-
tients with severe ILD and significant exertional hypoxemia
may not be able to train at a high enough intensity to gain
similar benefits from rehabilitation. Patients with a high
baseline walk distance had less improvement in 6MWD,
likely due to either their limited capacity for further
improvement (i.e. a ceiling effect) or regression to the
mean. However, a high baseline walk distance did not
predict lack of improvement in other functional and
symptomatic endpoints, suggesting that rehabilitation can
still be a valuable intervention in patients with a high
baseline functional capacity. Our sample size did not
permit detailed subgroup analyses, and there are still
limited data on whether all ILD subtypes derive similar
benefit from pulmonary rehabilitation.
Most functional and symptomatic improvements were
maintained on long-term follow-up, however our results are
limited by long-term losses to follow-up of just over a
quarter of patients. Most previous studies have handled this
limitation by using a complete-case analysis (i.e. removing
lost patients from the analysis) or using imputation methods
(e.g. last observation carried forward). We believe a
repeated measures regression is more appropriate in thissituation as it mitigates some sources of potential bias that
could exist due to preferential dropout of patients that may
have benefitted less from rehabilitation. ILD is a progres-
sive disease in many cases, so attenuation of improvements
over baseline may represent progression of disease rather
than waning effects of rehabilitation. A controlled study is
required to fully address this issue. Nonetheless, this
attenuation raises the question of whether there are stra-
tegies that could promote longer-lasting improvements
Pulmonary rehabilitation in interstitial lung disease 209(e.g. longer duration of rehabilitation, long-term telephone
follow-up).
Previous studies have shown that dyspnea severity is a
major determinant of quality of life in patients with ILD
[36]. However, we found that change in 6MWD (not change
in dyspnea) was the strongest correlate of change in quality
of life in ILD patients undergoing pulmonary rehabilitation.
This is likely due to the fact that rehabilitation improves
function (6MWD) more dramatically and durably than dys-
pnea, and that changes in quality of life are therefore more
likely due to these larger changes in function. Although it is
not possible to attribute cause and effect to the association
between change in 6MWD and change in quality of life, this
finding suggests that improving function has an important
role in increasing quality of life in patients with ILD. Pub-
lished data linking change in 6MWD to survival time suggest
that improving function may also impact mortality in ILD
[37]. Future study is required to address this more
completely.
In summary, there is now mounting evidence to support
pulmonary rehabilitation as a first line therapy in patients
with ILD. Importantly, most patients have clinically mean-
ingful benefit and these effects persist long-term in most
patients. Pulmonary rehabilitation is likely complementary
to pharmacological therapies, as it works through im-
provements in fitness and education. This has significant
implications for clinicians (who could prescribe pulmonary
rehabilitation in addition to any pharmacological therapy)
and for clinical trialists (where differences in rates of pul-
monary rehabilitation between arms could easily confound
efficacy results). Further research is required to confirm
which patients benefit most from rehabilitation, determine
whether there are components of rehabilitation that are
particularly valuable in patients with ILD, define the pa-
rameters of endurance and resistance exercise prescription
that result in maximal physiological benefits, and explore
whether there are strategies that can be used to enhance
rehabilitation’s long-term benefit.Source of funding
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